Asymptomatic systemic sarcoidosis arising 5 years after IFN-alpha treatment for chronic hepatitis C: a new challenge for clinicians.
Asymptomatic systemic sarcoidosis arising 5 years after IFN-alpha treatment for chronic hepatitis C: a new challenge for clinicians.
复制标题
IFN-α 治疗慢性丙型肝炎 5 年后出现的无症状系统性结节病：临床医生面临的新挑战。
DOI：
--
复制
发表时间：
2004
影响因子：
2.3
通讯作者：
S. Antonaci
中科院分区：
文献类型：
--
作者：
C. Tortorella;N. Napoli;E. Panella;A. Antonaci;A. Gentile;S. Antonaci
干扰素（IFN）诱导的结节病是有据可查的。在此，我们报告的情况下，慢性丙型肝炎（CHC）的病人谁开发干扰素-α诱导结节病。本病例的临床特征使其在迄今为止描述的所有病例中独一无二。事实上，该患者没有结节病的症状，在CHC随访期间偶然发现了以肝和肺肉芽肿为特征的疾病。诊断是在IFN-α停药后5年做出的。IFN-α在我们患者中的致病作用得到了在IFN-α治疗开始前进行的肝活检的支持，没有证据表明肉芽肿性定位。该病例表明IFN-α治疗期间结节病的发生率被低估了。在接受IFN-α治疗的CHC患者的随访中，应始终包括对该疾病典型的临床和实验室检查结果以及肝活检的搜索。
Interferon (IFN)-induced sarcoidosis is well documented. Herein, we report the case of a patient with chronic hepatitis C (CHC) who developed IFN-alpha-induced sarcoidosis. The clinical features of this case make it unique among all cases so far described. The patient was, in fact, asymptomatic for sarcoidosis, and the disease, characterized by liver and lung granulomatosis, was discovered by chance during the CHC follow-up. The diagnosis was made 5 years after IFN-alpha discontinuation. A pathogenetic role for IFN-alpha in our patient is supported by a liver biopsy performed before the therapy with IFN-alpha was started, showing no evidence of granulomatous localizations. This case suggests that the incidence of sarcoidosis during IFN-alpha treatment is underestimated. A search for clinical and laboratory findings typical of the disease, as well as a liver biopsy, should always be included in the follow-up of CHC patients undergoing therapy with IFN-alpha.
细胞和细胞因子参与结节病的发病机制。
DOI：
--
发表时间：
1999
期刊：
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
影响因子：
--
作者：
Moller,DR
通讯作者：
Moller,DR